These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36506763)

  • 1. Pembrolizumab-Induced Myasthenia Gravis and Myositis: Literature Review on Neurological Toxicities of Programmed Death Protein 1 Inhibitors.
    Schwab A; Assaad M; Hamadi R; Zurndorfer J; Abi Melhem R; Holtzbach J; Loeffler J; Ibrahim M
    J Med Cases; 2022 Nov; 13(11):530-535. PubMed ID: 36506763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitor-Induced Myositis/Myasthenia Gravis Overlap.
    Gosser C; Al Bawaliz A; Bahaj W; Chesney J; Ranjan S
    Cureus; 2023 Nov; 15(11):e49007. PubMed ID: 38111441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab-induced myasthenia gravis: A fatal case report.
    March KL; Samarin MJ; Sodhi A; Owens RE
    J Oncol Pharm Pract; 2018 Mar; 24(2):146-149. PubMed ID: 28147928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring Pembrolizumab-Induced Myocarditis, Myositis, and Myasthenia Gravis: A Comprehensive Literature Review and Case Presentation on Bladder Cancer.
    Shah D; Young K
    Cureus; 2023 Dec; 15(12):e49867. PubMed ID: 38169986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Rare Case of Overlapping Durvalumab-induced Myositis, Takotsubo-like Morphological Changes Caused by Myocarditis, and Myasthenia Gravis.
    Saito S; Hontsu S; Hiraoka J; Yamanaka A; Fujioka N; Shimada D; Okuda Y; Sugie K; Muro S
    Intern Med; 2024 Apr; ():. PubMed ID: 38658343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report.
    Tian CY; Ou YH; Chang SL; Lin CM
    J Med Case Rep; 2021 Apr; 15(1):244. PubMed ID: 33926558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Case of Pembrolizumab-Induced Myasthenia Gravis.
    Kosick TI; Patel K; Jasinski J; Dada B
    Cureus; 2023 Sep; 15(9):e45455. PubMed ID: 37859893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of myasthenia gravis and myositis induced by pembrolizumab].
    Noda T; Kageyama H; Miura M; Tamura T; Ito H
    Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myasthenia Gravis Associated With Programmed Death-1 (PD-1) Receptor Inhibitor Pembrolizumab: A 40-day Case Report.
    Ziobro AS; LaPlante RL; DeMari SR; Clark LM; Kingsley DJ; Smith AJ
    J Pharm Pract; 2021 Feb; 34(1):166-170. PubMed ID: 33143531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.
    Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N
    BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature.
    Yin B; Xiao J; Wang X; Li X; Guan Y; Chen J; Han P; Li K; Wang J
    Front Med (Lausanne); 2022; 9():950801. PubMed ID: 36457566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report.
    Saishu Y; Yoshida T; Seino Y; Nomura T
    J Med Case Rep; 2022 Feb; 16(1):61. PubMed ID: 35152911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report.
    Cham J; Ng D; Nicholson L
    J Med Case Rep; 2021 May; 15(1):278. PubMed ID: 34053457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous pembrolizumab-induced myasthenia gravis and myocarditis in a patient with metastatic bladder cancer: A case report.
    Takai M; Kato D; Iinuma K; Maekawa YM; Nakane K; Tsuchiya T; Yokoi S; Koie T
    Urol Case Rep; 2020 Jul; 31():101145. PubMed ID: 32190548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma.
    Hayakawa N; Kikuchi E; Suzuki S; Oya M
    Int Cancer Conf J; 2020 Jul; 9(3):123-126. PubMed ID: 32582515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab-induced peripheral nervous system damage: A combination of myositis/ myasthenia overlap syndrome and motor axonal polyneuropathy.
    Arman Ç; Ibrahim K; Elif OK; Hacer D; Yeşim P
    Ideggyogy Sz; 2023 Nov; 76(11-12):422-426. PubMed ID: 38051685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings-A Case Report and Literature Review.
    Giovannini E; Bonasoni MP; D'Aleo M; Tamagnini I; Tudini M; Fais P; Pelotti S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review.
    Wai Siu DH; O'Neill RS; Harris CA; Wang J; Ardolino L; Downton T; Tong M; Hong JH; Chin V; Clingan PR; Aghmesheh M; Soudy H
    Immunotherapy; 2022 May; 14(7):511-520. PubMed ID: 35321560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis.
    Ishii A; Yokoyama M; Tsuji H; Fujii Y; Tamaoka A
    eNeurologicalSci; 2020 Jun; 19():100236. PubMed ID: 32211521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylcholine receptor binding antibody-associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review.
    Wang S; Peng D; Zhu H; Min W; Xue M; Wu R; Shao Y; Pan L; Zhu M
    Front Oncol; 2022; 12():1053370. PubMed ID: 36568231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.